Open AccessEfficacy of α‐glucosidase inhibitors combined with dipeptidyl‐peptidase‐4 inhibitor (alogliptin) for glucose fluctuation in patients with type 2 diabetes mellitus by continuous glucose monitoring
Author(s) -
Kurozumi Akira,
Okada Yosuke,
Mori Hiroko,
Arao Tadashi,
Tanaka Yoshiya
Publication year - 2013
Publication title -
journal of diabetes investigation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.089
H-Index - 50
eISSN - 2040-1124
pISSN - 2040-1116
DOI - 10.1111/jdi.12059
Subject(s) - alogliptin , dipeptidyl peptidase 4 inhibitor , medicine , postprandial , type 2 diabetes , diabetes mellitus , glycemic , type 2 diabetes mellitus , dipeptidyl peptidase 4 , endocrinology , pharmacology , gastroenterology
Aims/Introduction The combination therapy of dipeptidyl‐peptidase ( DPP )‐4 inhibitor and α‐glucosidase inhibitors (α‐ GI s) is highly effective in suppressing postprandial hyperglycemia. The aim of the present study was to compare the effects of voglibose and miglitol on glucose fluctuation, when used in combination with DPP ‐4 inhibitor by using continuous glucose monitoring ( CGM ). Materials and Methods In a randomized cross‐over study, 16 patients with type 2 diabetes who presented with postprandial hyperglycemia despite alogliptin (25 mg) were treated with voglibose (0.9 mg) or miglitol (150 mg). We measured standard deviation ( SD ); mean amplitude of glycemic excursions ( MAGE ), and mean, minimum and maximum glucose measured by CGM during three phases (alogliptin monotherapy, dual therapy of alogliptin and voglibose, and dual therapy of alogliptin and miglitol). The primary outcome measure was SD between α‐ GI s. Results SD was significantly improved by the addition of either voglibose (18.9 ± 10.1) or miglitol (19.6 ± 8.2) to alogliptin monotherapy (36.2 ± 8.7). MAGE improved significantly with the addition of either voglibose (57.5 ± 26.1, P < 0.01) or miglitol (64.6 ± 26.2, P < 0.01) to alogliptin monotherapy (101.5 ± 21.5). There was no significant difference in glucose fluctuation between α‐ GI s. There were no differences between two groups in mean (132.6 ± 21.4 and 138.7 ± 25.4) and maximum (184.3 ± 48.7 and 191.9 ± 38.3). The minimum glucose under alogliptin plus voglibose (94.9 ± 20.2) was significantly lower than that under alogliptin and miglitol (105.3 ± 21.0). Conclusions Glucose fluctuation was improved by the addition of voglibose or miglitol to alogliptin. Glucose fluctuations and postprandial hyperglycemia were similar between α‐ GI s. This trial was registered with the University Hospital Medical Information Network (no. UMIN R000010028).